Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use

FIGURE 1. Analysis of efficacy outcomes in patients receiving/not receiving a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). The cardiovascular composite outcome included time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The kidney composite outcome included time to kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline from baseline, or renal death. CI, confidence interval; PY, patient‐years

FIGURE 2. Change in urine albumin‐to‐creatinine ratio over time in patients receiving/not receiving a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) at baseline. P‐interaction at 4 months derived from analysis of covariance = 0.0305. Mixed model with factors treatment group, region, estimated glomerular filtration rate category at screening, type of albuminuria at screening, time, treatment*time, study, study*treatment, log‐transformed baseline value nested within type of albuminuria at screening, and log‐transformed baseline value*time as covariate. CI, confidence interval; LS, least squares

FIGURE 3. Efficacy outcomes considering the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use at any time on‐treatment. The cardiovascular composite outcome included time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The kidney composite outcome included time to kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline from baseline, or renal death. *Interaction P‐value for adjusted hazard ratio is based on a two‐sided Wald test. CI, confidence interval

FIGURE 4. Forest plot of analysis of covariance for ratio to baseline at Month 4 of urine albumin‐to‐creatinine ratio (UACR) by glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitor use at baseline (full analysis set). Per subgroup category an ANCOVA with factors treatment group, region, eGFR category at screening, type of albuminuria at screening, cardiovascular disease history, study, log‐transformed baseline value nested within type of albuminuria and the interaction between study and treatment was applied. For Month 4, the closest observation to Day 120 within a time window of 120 ± 30 days after randomization was used. Patients with no measurements within this time window were excluded from the analysis. *Geometric mean of the ratio of UACR at Month 4 to baseline. CI, confidence interval; LS, least squares